Analysts Set Expectations for IQVIA’s Q1 Earnings (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQV) – Equities researchers at Zacks Research reduced their Q1 2025 earnings estimates for shares of IQVIA in a research report issued on Thursday, November 21st. Zacks Research analyst R. Department now forecasts that the medical research company will earn $2.34 per share for the quarter, down from their prior estimate of $2.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Zacks Research also issued estimates for IQVIA’s Q2 2025 earnings at $2.59 EPS and FY2025 earnings at $10.58 EPS.

A number of other research analysts also recently issued reports on IQV. BTIG Research dropped their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, TD Cowen lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Down 1.4 %

Shares of IQV opened at $201.24 on Monday. The stock has a market capitalization of $36.53 billion, a price-to-earnings ratio of 26.41, a PEG ratio of 2.08 and a beta of 1.51. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a fifty day moving average of $221.18 and a 200-day moving average of $226.75.

Institutional Trading of IQVIA

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA during the 3rd quarter worth $147,683,000. 1832 Asset Management L.P. increased its holdings in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC bought a new stake in IQVIA during the 2nd quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc boosted its stake in IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.